Back to Acceleration Radar
NTLAIntellia Therapeutics Inc
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · Small
$11.21+0.45%
As of 23 Oct 2026Mkt cap $1.8B
Stage 13
AVOID
Fundamentals
10.0/75
Technical
3.8/15
Independent
13.8/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- −7.8%
- 3M
- +5.1%
- 6M
- −17.8%
- 1Y
- −54.4%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- —
- Operating margin
- -923.1%
- FCF margin
- -585.0%
- Current ratio
- 5.1x
Growth
- Revenue growth
- +16.9%Latest FY YoY
- Revenue CAGR
- +19.6%
- EPS CAGR
- —
- FCF CAGR
- —
Capital
- Share-count trend
- +10.5%3Y annualised
- Net cash
- $62M
Annual trend
- CAGR 2021–2025
- +19.6%
- Latest · 2025
- $0B
- YoY
- +16.9%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-05
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded